A Taiwan study found a significantly reduced risk of cancer among RA patients on biologics.
A nationwide study, conducted in Taiwan between 1999-2011 using the Taiwan National Health Insurance Research Database, compared the risk of cancer diagnosis in patients with rheumatoid arthritis who were administered the TNF-α antagonists versus non-biological disease-modifying anti-rheumatic drugs (nbDMARDs). The study identified a significantly reduced incidence rate of cancer among patients using biologics, and modified Cox proportional hazards analysis showed a much lower risk in the biologics cohort of 4426 users of TNF-α antagonists (HR 0.63, 95% CI 0.49—0.80, P <.001). There was however an increased risk of hematological cancers in the biologics cohort.
Link to the paper in Arthritis Research and Therapy: http://bit.ly/1uVJHWe
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More